639 related articles for article (PubMed ID: 18371480)
1. High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
Anderson RE; Pfeffer MA; Thune JJ; McMurray JJ; Califf RM; Velazquez E; White HD; Rouleau JL; Skali H; Maggioni A; Solomon SD
Am Heart J; 2008 Apr; 155(4):706-11. PubMed ID: 18371480
[TBL] [Abstract][Full Text] [Related]
2. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
Aguilar D; Solomon SD; Køber L; Rouleau JL; Skali H; McMurray JJ; Francis GS; Henis M; O'Connor CM; Diaz R; Belenkov YN; Varshavsky S; Leimberger JD; Velazquez EJ; Califf RM; Pfeffer MA
Circulation; 2004 Sep; 110(12):1572-8. PubMed ID: 15364810
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
Califf RM; Lokhnygina Y; Velazquez EJ; McMurray JJ; Leimberger JD; Lewis EF; Diaz R; Murin J; Pfeffer MA
Am J Cardiol; 2009 Jul; 104(2):151-7. PubMed ID: 19576338
[TBL] [Abstract][Full Text] [Related]
4. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
White HD; Aylward PE; Huang Z; Dalby AJ; Weaver WD; Barvik S; Marin-Neto JA; Murin J; Nordlander RO; van Gilst WH; Zannad F; McMurray JJ; Califf RM; Pfeffer MA;
Circulation; 2005 Nov; 112(22):3391-9. PubMed ID: 16301343
[TBL] [Abstract][Full Text] [Related]
5. Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial.
Kenchaiah S; Davis BR; Braunwald E; Rouleau JL; Dagenais GR; Sussex B; Steingart RM; Brown EJ; Lamas GA; Gordon D; Bernstein V; Pfeffer MA;
Am Heart J; 2004 Aug; 148(2):356-64. PubMed ID: 15309009
[TBL] [Abstract][Full Text] [Related]
6. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
[TBL] [Abstract][Full Text] [Related]
7. Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial.
Moukarbel GV; Signorovitch JE; Pfeffer MA; McMurray JJ; White HD; Maggioni AP; Velazquez EJ; Califf RM; Scheiman JM; Solomon SD
Eur Heart J; 2009 Sep; 30(18):2226-32. PubMed ID: 19556260
[TBL] [Abstract][Full Text] [Related]
8. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.
Anavekar NS; McMurray JJ; Velazquez EJ; Solomon SD; Kober L; Rouleau JL; White HD; Nordlander R; Maggioni A; Dickstein K; Zelenkofske S; Leimberger JD; Califf RM; Pfeffer MA
N Engl J Med; 2004 Sep; 351(13):1285-95. PubMed ID: 15385655
[TBL] [Abstract][Full Text] [Related]
9. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
[TBL] [Abstract][Full Text] [Related]
10. Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT).
Shamshad F; Kenchaiah S; Finn PV; Soler-Soler J; McMurray JJ; Velazquez EJ; Maggioni AP; Califf RM; Swedberg K; Kober L; Belenkov Y; Varshavsky S; Pfeffer MA; Solomon SD;
Am Heart J; 2010 Jul; 160(1):145-51. PubMed ID: 20598985
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience.
Stephenson K; Skali H; McMurray JJ; Velazquez EJ; Aylward PG; Kober L; Van de Werf F; White HD; Pieper KS; Califf RM; Solomon SD; Pfeffer MA
Heart Rhythm; 2007 Mar; 4(3):308-13. PubMed ID: 17341394
[TBL] [Abstract][Full Text] [Related]
12. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
[TBL] [Abstract][Full Text] [Related]
13. Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial.
Anand IS; Rector TS; Kuskowski M; Thomas S; Holwerda NJ; Cohn JN
Circ Heart Fail; 2008 May; 1(1):34-42. PubMed ID: 19808268
[TBL] [Abstract][Full Text] [Related]
14. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Reed SD; Radeva JI; Weinfurt KP; McMurray JJ; Pfeffer MA; Velazquez EJ; Allsbrook JS; Masselink LE; Sellers MA; Califf RM; Schulman KA;
Am Heart J; 2005 Aug; 150(2):323-9. PubMed ID: 16086938
[TBL] [Abstract][Full Text] [Related]
15. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial.
Zanchetti A; Julius S; Kjeldsen S; McInnes GT; Hua T; Weber M; Laragh JH; Plat F; Battegay E; Calvo-Vargas C; Cieśliński A; Degaute JP; Holwerda NJ; Kobalava J; Pedersen OL; Rudyatmoko FP; Siamopoulos KC; Störset O
J Hypertens; 2006 Nov; 24(11):2163-8. PubMed ID: 17053536
[TBL] [Abstract][Full Text] [Related]
16. Smoking as an independent risk factor for myocardial infarction or stroke in type 2 diabetes: a report from the Swedish National Diabetes Register.
Nilsson PM; Cederholm J; Eeg-Olofsson K; Eliasson B; Zethelius B; Fagard R; Gudbjörnsdóttir S;
Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16(4):506-12. PubMed ID: 19561510
[TBL] [Abstract][Full Text] [Related]
17. Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction.
Khan SQ; Ng K; Dhillon O; Kelly D; Quinn P; Squire IB; Davies JE; Ng LL
Eur Heart J; 2009 May; 30(9):1057-65. PubMed ID: 19168526
[TBL] [Abstract][Full Text] [Related]
18. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
Solomon SD; Skali H; Anavekar NS; Bourgoun M; Barvik S; Ghali JK; Warnica JW; Khrakovskaya M; Arnold JM; Schwartz Y; Velazquez EJ; Califf RM; McMurray JV; Pfeffer MA
Circulation; 2005 Jun; 111(25):3411-9. PubMed ID: 15967846
[TBL] [Abstract][Full Text] [Related]
19. The case for chronic kidney disease, diabetes mellitus, and myocardial infarction being equivalent risk factors for cardiovascular mortality in patients older than 65 years.
Rashidi A; Sehgal AR; Rahman M; O'Connor AS
Am J Cardiol; 2008 Dec; 102(12):1668-73. PubMed ID: 19064021
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of acute coronary syndrome in a large Canadian cohort: impact of chronic renal insufficiency, cardiac interventions, and anemia.
Keough-Ryan TM; Kiberd BA; Dipchand CS; Cox JL; Rose CL; Thompson KJ; Clase CM
Am J Kidney Dis; 2005 Nov; 46(5):845-55. PubMed ID: 16253724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
